Vioxx risks can occur within 2 weeks: Canada study

Key points
- The risk of taking the painkiller Vioxx is more acute than previously thought, according to research published online Tuesday in the Canadian Medical Association Journal.
- One quarter of patients who suffered a heart attack did so within the first 2 weeks of taking their first Vioxx prescription, a McGill University Health Center study revealed.
- "The additional cardiovascular risk from Vioxx actually decreased with longer duration of use, suggesting that the period of highest susceptibility for most people taking Vioxx may occur earlier than previously believed," said Linda Levesque, the lead author of the study.
- Inc. pulled the $2.5 billion-a-year drug from the market in September 2004 after a study showed Vioxx doubled heart attack and stroke risk for patients who took it for 18 months or longer.
The risk of taking the painkiller Vioxx is more acute than previously thought, according to research published online Tuesday in the Canadian Medical Association Journal.
One quarter of patients who suffered a heart attack did so within the first 2 weeks of taking their first Vioxx prescription, a McGill University Health Center study revealed.
"The additional cardiovascular risk from Vioxx actually decreased with longer duration of use, suggesting that the period of highest susceptibility for most people taking Vioxx may occur earlier than previously believed," said Linda Levesque, the lead author of the study.
Merck & Co. Inc. pulled the $2.5 billion-a-year drug from the market in September 2004 after a study showed Vioxx doubled heart attack and stroke risk for patients who took it for 18 months or longer.
A Texas jury found last month that the painkiller caused the death of a 71-year-old man who had taken the drug for less than 1 month, and awarded his family damages of $32 million.
Merck faces about 10,000 Vioxx related lawsuits.
The Canadian study assessed the pattern of cardiovascular risk in seniors over a 3-year period to establish the timing of the Vioxx risk.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Addiction →
NewsMore problems for Merck over Vioxx
The painkiller Vioxx was withdrawn from the market in 2004 following a three-year study which showed it doubled the risk of heart attack and strokes in patients taking it for at least 18 months. Vioxx belongs to a class…
28 June 2006
NewsFDA warns of possible risks to children using Triaminic Vapor Patch
The U.S. Food and Drug Administration (FDA) today is warning consumers not to use the Triaminic Vapor Patch marketed by Novartis Consumer Health due to reports of serious adverse events associated with accidental…
21 June 2006
NewsVioxx risk seen with short-term use: report
Merck & Co. Inc. has provided new data to U.S. regulators showing that all patients who took the arthritis medicine Vioxx were at increased risk of heart attacks, strokes and other complications, National Public Radio…
19 May 2006
